Despite the challenges of COVID-19, OHG agencies have continued to thrive. We’ve supported nearly a half-dozen new product launches for clients, creating and delivering critical communications support for important healthcare brands. We also formed a cross-agency advisory to identify challenges surrounding remote work, hack problems, and provide work-from-home support for our employees. Our agencies have undertaken and produced several research projects to assess the impact of COVID-19 on the broader healthcare landscape. Click on the links below to see how we’re counseling clients on navigating the pandemic.
Omnicom Health Group
Contact: Christina Kim
How are pharma companies adopting marketing technology due to the shift from face-to-face engagement to primarily digital communications? What are the opportunities to strengthen digital capabilities that enable a modern healthcare customer engagement? We surveyed advertising organizations in pharma marketing to uncover the current and planned usage of technology in 12 areas of the marketing technology stack.
Omnicom Health Group
Contact: David Madapur
In February, Omnicom Health Group put forth a paper highlighting the technology trends that would shape healthcare in 2020. Since that time, the coronavirus pandemic has altered the world as we knew it and brought our reliance on technology to the fore. Hence we decided to refresh our research and see how COVID-19 affected our predictions and the role the projected digital health trends are playing in the fight against COVID-19.
Entrée Health
Contact: Lauren Elliott
If field teams do not have live access to HCP offices at launch, what key strategies do we deploy to effectively reach and increase share of voice quickly? We provide tips and processes on how we can think about activating our sales force teams differently to make the most impact for our brands.
SNOW Companies
Contact: Brenda Snow
The world for patients is currently in constant flux, and as such, we need to understand the many challenges patients are facing today and quickly adapt and implement solutions to address their needs. In this document, you’ll read about a survey SNOW companies conducted to learn about how patients are experiencing disruptions in their overall treatment, how they are navigating virtual relationships with their doctors, and much more.
Harrison and Star
Contact: Dan Reed
The purpose of this overview is to show how the practice of oncology is changing during the novel coronavirus (COVID-19) pandemic. Here, we try to anticipate some of the long-term challenges of the pharmaceutical industry and begin to sketch out possible approaches we can take to be relevant and helpful now and in the future.
Patients & Purpose
Contact: John Deeley
As the COVID-19 pandemic continues to play out around the world, people in real life are practicing social distancing. But in the virtual world, social media is bringing people closer together in new and inspiring ways. As healthcare brands, it is imperative we consider what our role should be and how to best support our patients in challenging times. Here, we discuss some practical steps we can take to evaluate where your brand is on social today and how we can quickly pivot to be more relevant for our patients during this time.
SSCG Media
Contact: Sandra Parrelli
When the COVID-19 pandemic started to unfold, and the pharmaceutical industry began grappling with the reality of sales force and live event disruption, conversations sparked around how to fill the void with non-personal promotion. But questions also circulated about ensuring pharma strikes the right level of presence and the right tone with healthcare professionals who are facing immense disruption and uncertainty. So, we went to the source and asked healthcare professionals directly. Our data and findings help fuel recommendations on how to engage with HCPs during these times.
CDM New York
Contact: Kristen Gengaro
CDM conducted an analysis of the collective response to the COVID-19 pandemic, as well as observations of how brands are responding to the global crisis. Based on these observations, we’ve put forth recommendations on how pharmaceutical brands should behave during this crisis and beyond based on the spectrum of human response to COVID-19.